Skip to main content
. 2011 Aug 18;6(8):e23758. doi: 10.1371/journal.pone.0023758

Figure 8. CLL cells from patients with different risk-groups are equally protected by stromal cells but cells from high-risk patients are able to adhere in higher numbers.

Figure 8

(A) VCAM-1 expression on M2-10B4 cells was detected by flow cytometry. (B) PBMCs from CLL patients were cultured in the absence or presence of M2-10B4 cells for 48 hours. VLA-4 and CD38 expression levels on viable CD19+CD5+ CLL cells were determined by flow cytometry at indicated time points. (n = 5, Repeated Measures ANOVA, VLA-4, p = .0083; CD38, p = .1681; Bonferroni's Multiple Comparision Test) (C-F) PBMCs from CLL patients were co-cultured with M2-10B4 cells and after 48 hours viability and adhesion of CLL cells was determined by flow cytometry. (C) Viability of CLL cells from patients with low (n = 7) and high (n = 7) VLA-4-risk left untreated (Mann Whitney test, p = .9015) or treated with 5 µM fludarabine (Unpaired t-test, p = .4626). (D) Adhesion of CLL cells to M2-10B4 of different patient risk-groups (a, VLA-4, low, n = 7; high, n = 7; Unpaired t-test, p = .0003; b, CD38, low, n = 9; high, n = 5, Unpaired t-test, p = .0560). (E) Adhesion of CLL cells to M2-10B4 cells of VLA-4 low-risk (n = 7) or high-risk (n = 7) patient samples pretreated with isotype control (Control) or anti-VLA-4 antibodies. (Paired t-test, low-risk: p = ,4876; high-risk: p = .0059) (F) Viability of non-adherent and adherent CLL cells to M2-10B4 cells of VLA-4 low-risk (n = 7, Paired t test, p = .1186) or high-risk (n = 7, Wilcoxon signed rank test, p = .5781) patient samples. **, P<.01, ***, P<.001.